Dell Technologies Inc (NASDAQ:DELL) shares hit an all-time high above $562, up 11% on Friday after RBC Capital Markets initiated coverage with an Outperform rating and a $640 price target.
RBC's initiation cited enterprise demand for AI investments, compute modernization, storage expansion and PC refresh, which the firm said should sustain results above Dell's long-term targets.
American Eagle Outfitters Inc. (NYSE:AEO) shares fell nearly 16% Thursday after mixed second-quarter results, with revenue modestly above consensus even as reported earnings got a significant boost from tariff refunds.
Consolidated sales rose 8% to $1.38 billion, with comparable sales up 6%, led by Aerie and improving trends at the core American Eagle brand.
Apple Inc (NASDAQ:AAPL, XETRA:APC) had a good Thursday, with shares up 3.1% after unveiling its first foldable iPhone, the $1,999-and-up iPhone Duo.
The move puts Apple into a market Samsung, Google and Huawei have played in for years – the biggest shake-up to the iPhone lineup in a long time.
Adobe Inc (NASDAQ:ADBE) is expected to report fiscal third-quarter results largely in line with guidance, according to Jefferies, as investors weigh a surprise leadership change alongside ongoing questions about the software giant's ability to fend off disruption from AI-native tools.
Jefferies expects Adobe revenue of $6.7 billion, near guidance midpoint, implying 11.8% growth, a deceleration from 12.7% due to tougher comps despite Semrush's contribution. Operating margin is modeled at 44%, down year-over-year as Adobe prioritizes user acquisition over monetization. The firm expects reiterated fiscal 2026 ARR growth of 10.2%.
Oracle Corp (NYSE:ORCL, XETRA:ORC) reports fiscal first-quarter 2027 results Thursday afternoon, with Wall Street split between concerns over ballooning capital expenditures and optimism that data center capacity additions could reaccelerate revenue growth.
Bank of America is modeling infrastructure-as-a-service growth of 116% year-over-year and total revenue growth of 28%, up from 21% in the fourth quarter of fiscal 2026.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares.
The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target price of 11,500 pence.
Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD).
The data, from the open-label Part C portion of Study '005, showed sustained efficacy with an infrequent dosing paradigm of two to four times per year.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus.
Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab reduced flare-ups in chronic obstructive pulmonary disease (COPD).
JP Morgan has upgraded Kingspan Group PLC (ISE:KRX), the Irish building materials group, to 'overweight' from 'neutral', citing strong earnings momentum from its data centre exposure that it believes is not fully reflected in the valuation.
Order intake on data solutions for Kingspan's Advnsys segment has nearly quadrupled, yet the shares trade on 13 times 12-month forward EV/EBITDA, a discount of around 7% to their long-term average.
Brent crude passed $100 a barrel on Wednesday for the first time since July, as fresh strikes between the United States and Iran stoked fears of wider disruption to Middle East energy supplies.
The international benchmark traded as high as $100.44, up more than 2.5% on the day, while West Texas Intermediate rose to $94.92.
Hannam & Partners has raised its price target on Power Metallic Mines Inc (TSX-V:PNPN, FRA:IVV1, OTCQB:PNPNF) by 13% to C$2.70 per share, from C$2.38 previously, after the company released a maiden mineral resource estimate for its Lion deposit alongside an updated estimate at Nisk.
The 2026 Lion MRE outlines 4.75 million tonnes grading 3.9% copper equivalent, containing 80,500 tonnes of copper, 528,000 ounces of platinum group metals and 72,000 ounces of gold, with 87% of the resource classified as Indicated.
Aritzia Inc (TSX:ATZ) remains an "EPS compounder" whose long-term growth story is being underappreciated by investors focused on near-term comp sales normalization, according to UBS, which reiterated a Buy rating on the retailer with a C$216 price target.
The brokerage forecasts roughly 15% revenue and 26% EPS compound annual growth rates through fiscal 2031, driven by US expansion, digital growth and margin expansion. UBS said this growth profile positions Aritzia as a niche compounder capable of continued outperformance within the specialty retail sector, justifying a premium valuation.
EchoStar (NASDAQ:ECHO) shares got a boost Tuesday after UBS resumed coverage of the stock with a Buy rating and a $150 price target, sending the stock up 4.2%.
The UBS upgrade reflects EchoStar's transformation from wireless operator to investment vehicle, following the company's sale of 75-80% of its spectrum portfolio for roughly $43 billion.EchoStar is set to hold a 2% stake in SpaceX, equal to about 262 million shares, once its pending spectrum transaction closes. The deal is expected to close in November 2027 and has already received FCC approval. UBS valued that stake at roughly $39 billion, or $110 per EchoStar share, based on the current SpaceX stock price, and at $55 billion, or $156 per share, using the firm's $210 SpaceX price target.
Apple Inc (NASDAQ:AAPL, XETRA:APC) is set to unveil its first foldable iPhone alongside a refreshed Pro lineup, in John Ternus's first major product launch as CEO.
The event, dubbed "Surprise and shine," is scheduled for Wednesday at 1pm ET. Media reports cited in the note indicate the foldable iPhone, which could be named Fold or Ultra, will start at $2,099 for the base configuration, making it Apple's most expensive iPhone to date.
Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares.
The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer.
